Are you a journalist? Please sign up here for our press releases
Subscribe to our monthly newsletter:
Showing results for: ���� ������
https://wis-wander.weizmann.ac.il/space-physics/biorecognition
September 12, 2010
Since the 1960s, Prof. Meir Wilchek has studied "biorecognition”: the process in which biological substances "recognize" one another and form a bond. In particular, Wilcheck and his colleagues have focused on the strongest biological bond in nature, formed by the egg-white p...
https://wis-wander.weizmann.ac.il/life-sciences/immune-cancer-therapy
September 12, 2010
Since completing his Ph.D. in immunology at the Weizmann Institute, Prof. Zelig Eshhar has focused his research on molecular recognition in the immune system – the mechanisms by which immune cells and molecules "recognize" one another. In the late 1980s, he developed an immune ca...
https://wis-wander.weizmann.ac.il/life-sciences/developing-new-therapies-spinal-cord-injury
September 12, 2010
In the early 1980s, Prof. Michal Schwartz, an immunologist, started to explore the cross-talk between the immune and nervous systems. Application New therapies for spinal cord injury based on original concepts proposed by Schwartz are being developed and test...
https://wis-wander.weizmann.ac.il/earth-sciences/photodynamic-therapy-cancer
September 12, 2010
Prof. Avigdor Scherz studied photosynthesis, the process by which plants capture sunlight and convert it into useful energy. Together with Prof. Yoram Salomon, he developed light-sensitive compounds that successfully treated cancer in laboratory animals. The compounds are based o...
https://wis-wander.weizmann.ac.il/life-sciences/vaccine-type-1-diabetes
September 12, 2010
Prof. Irun Cohen discovered that a key protein in pancreatic cells, known as HSP60, can prompt an attack by immune T cells. He later showed that injecting diabetic mice with a small fragment of HSP60 shuts down this immune response, preventing the progression of type 1 diabe...
https://wis-wander.weizmann.ac.il/life-sciences/first-discovery-cancer-produced-protein-fusion
September 12, 2010
In the 1980s, Prof. Eli Canaani isolated two genes that abnormally swap pieces of genetic material and lead to the production of a fused protein that triggers chronic myelogenous leukemia (CML). It was the first discovery of cancer produced by protein fusion. Applicati...
https://wis-wander.weizmann.ac.il/life-sciences/hormone-erythropoietin-treating-multiple-myeloma
September 12, 2010
Prof. Emeritus Nechama Haran-Ghera, in collaboration with Israeli physicians, showed that the hormone erythropoietin may be helpful in treating multiple myeloma and other cancers. In mice injected with myeloma cells, the hormone prolonged survival, caused tumor regression an...
https://wis-wander.weizmann.ac.il/life-sciences/asthma-drug-used-enhance-ovarian-and-lung-cancer-treatment
September 12, 2010
Prof. Avraham Amsterdam revealed that theophylline, a widely used asthma drug, makes ovarian and lung cancer cells more vulnerable to common anticancer medications. Application Clinical trials in which theophylline is administered to lung cancer patients in c...
https://wis-wander.weizmann.ac.il/space-physics/advanced-radiation-detectors
September 12, 2010
Prof. Amos Breskin develops advanced radiation detectors, which have an important impact on many fields of research, such as particle, nuclear and atomic physics, medical diagnostics, biology and materials science. Application Together with colleagues at Weiz...
https://wis-wander.weizmann.ac.il/life-sciences/hepatitis-b-and-c-therapies
September 12, 2010
Prof. Yair Reisner developed mice with functioning human immune systems. These laboratory animals can be used for research on a broad range of human diseases. Application XTL Biopharmaceuticals Ltd. in Rehovot was set up to make use of Reisner’s technology. T...
Pages
Press Releases
Weizmann in the Media
The Sun
18.11.2020
Times of Israel
18.11.2020